Device Trial Radar · NCT06931821
Functional ElectroAnatomiC Isochronal Late Activation Mapping for Empiric VT Ablation Trial
Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
360
Planned (sponsor's estimate)
Start
Apr 15, 2025
Primary completion
Apr 30, 2028
Study completion Apr 30, 2029
Sponsor
- Lead sponsor
- University of ArizonaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Abbott
- First posted
- Apr 17, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, prospective, parallel, randomized controlled trial to test for non-inferiority with an ILAM-guided VT ablation compared to conventional voltage- based ablation. The study has two treatment arms: conventional voltage mapping and ablation (control arm). In the investigational arm, the ablation strategy is guided by ILAM to target deceleration zones, blinded to voltage mapping. In the control arm, ablation will be performed to extensively ablate all low voltage regions (\<1.5mV) during sinus rhythm, right ventricular (RV) pacing, or left ventricular (LV) pacing, with discretionary use of pacemapping and activation mapping. In both arms, mapping with be performed with a multielectrode catheter (HD Grid) and ablation will be performed using an irrigated tip catheter (FlexAbility SE or Tactiflex catheters). In the control armonly voltage mapping displays will be utilized (blinded to functional ILAM and fractionation). High density mapping with automated last deflection annotation (Ensite X) will be performed in all patients randomized to ILAM approach during either sinus rhythm or RV pacing.
Conditions
- Sustained Monomorphic VT (MMVT)
- Recurrent Ventricular Tachycardia
Interventions
Isochronal Late Activation Mapping (ILAM)Device
an isochronal late activation mapping (ILAM) display with automated last deflection annotation (EnSite X™) will be used to identify regions of isochronal crowding around a line of conduction block for targeted ablation therapy using a standard irrigated tip catheter (Flexability SE \& Tactiflex catheters)
High Density Voltage MappingDevice
high-density voltage mapping will serve as the method to display the electroanatomic substrate for extensive and diffuse ablation within the low voltage area (\<1.5 mV).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Inducibility for VTTime frame: after initial 25 minutes of ablation (minutes of radiofrequency)
- Recurrent VTTime frame: 1 year post procedure
- CV HospitalizationTime frame: 1 year post procedure
2 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Banner University Medical Center Phoenix
Phoenix, Arizona · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.